Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Merkel Cell Carcinoma With Gastric Metastasis and Review of Literature.

Hu ZI, Schuster JA, Kudelka AP, Huston TL.

J Cutan Med Surg. 2016 May;20(3):255-8. doi: 10.1177/1203475415623509. Epub 2015 Dec 16. Review.

PMID:
26676953
2.

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.

Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB.

Cancer Chemother Pharmacol. 2009 Apr;63(5):903-10. doi: 10.1007/s00280-008-0813-8. Epub 2008 Aug 6.

PMID:
18682950
3.

Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Lee SJ, Gounder M, Rubin EH, Li JM, Gu Z, Thalasila A, Loyer E, Kudelka AP, Verschraegen CF.

Invest New Drugs. 2008 Dec;26(6):541-51. doi: 10.1007/s10637-008-9147-y. Epub 2008 Jul 4.

PMID:
18600301
4.

Visual vignette.

Kraeher A, Eledrisi MS, Lieberman S, Kudelka AP.

Endocr Pract. 2005 Nov-Dec;11(6):412. No abstract available.

PMID:
16638731
5.

Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance.

See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):209-16.

PMID:
15823101
6.

Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.

Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ.

Proteomics. 2003 Oct;3(10):1904-11.

PMID:
14625852
7.

Physiological and psychological effects of delivering medical news using a simulated physician-patient scenario.

Cohen L, Baile WF, Henninger E, Agarwal SK, Kudelka AP, Lenzi R, Sterner J, Marshall GD.

J Behav Med. 2003 Oct;26(5):459-71.

PMID:
14593853
8.

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R.

Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. Epub 2003 Oct 28.

PMID:
14586557
9.

Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12.

Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS.

J Immunother. 2003 May-Jun;26(3):270-6.

PMID:
12806280
10.

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.

Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC.

Clin Cancer Res. 2003 Feb;9(2):845-52.

11.

Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.

Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS.

Clin Cancer Res. 2002 Dec;8(12):3686-95.

12.

An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines.

Le Blanc M, Russo J, Kudelka AP, Smith JA.

Pharmacol Res. 2002 Dec;46(6):551-5.

PMID:
12457630
13.

Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study.

Gordinier ME, Kudelka AP, Kavanagh JJ, Wharton JT, Freedman RS.

Int J Gynecol Cancer. 2002 Nov-Dec;12(6):710-4.

PMID:
12445247
14.

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG.

Clin Cancer Res. 2002 Nov;8(11):3407-18.

15.

Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.

Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O'Brian CA, Ioannides CG.

J Immunol. 2002 Oct 1;169(7):3545-54.

16.

Treatment with HER-2 phosphorylation agonists enhance tumor ability to stimulate epitope specific CTL in vitro.

Castilleja A, Ward NE, Epstein RB, Kudelka AP, Gershenson DM, Efferson CL, O'Brian CA, Ioannides CG.

Oncol Rep. 2002 Sep-Oct;9(5):929-35.

PMID:
12168050
17.

Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.

Azevedo P, Verschraegen CF, Kavanagh JJ, Kudelka AP, Freedman RS, Lu K, Deavers MT.

Eur J Gynaecol Oncol. 2001;22(5):319-21. No abstract available.

PMID:
11766729
18.

Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.

Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka-Bevers D, Kudelka AP, Hu W, Vincent M, Nelson T, Levenback C; Community Clinical Oncology Program.

Cancer. 2001 Nov 1;92(9):2327-33.

PMID:
11745287
19.

Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy.

Lenert JT, Barnett CC Jr, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, Skibber JM, Ross MI, Pisters PW, Curley SA, Evans DB, Lee JE.

Surgery. 2001 Dec;130(6):1060-7.

PMID:
11742339
20.

Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later.

Verschraegen CF, Benjapibal M, Supakarapongkul W, Levy LB, Ross M, Atkinson EN, Bodurka-Bevers D, Kavanagh JJ, Kudelka AP, Legha SS.

Int J Gynecol Cancer. 2001 Sep-Oct;11(5):359-64.

PMID:
11737466
21.

Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma.

Hosing C, Freedman RS, McLaughlin P, Malpica A, Fornage BD, Kudelka AP.

Am J Clin Oncol. 2001 Apr;24(2):204-8.

PMID:
11319299
22.

Breaking bad news about cancer: patients' preferences for communication.

Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L.

J Clin Oncol. 2001 Apr 1;19(7):2049-56.

PMID:
11283138
23.

Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.

Castilleja A, Ward NE, O'Brian CA, Swearingen B 2nd, Swan E, Gillogly MA, Murray JL, Kudelka AP, Gershenson DM, Ioannides CG.

Mol Cell Biochem. 2001 Jan;217(1-2):21-33.

PMID:
11269662
24.

Octreotide induced remission of a refractory small cell carcinoma of the endometrium.

Verschraegen CF, Matei C, Loyer E, Malpica A, Tornos C, Kudelka AP, Kavanagh JJ.

Int J Gynecol Cancer. 1999 Jan;9(1):80-85.

PMID:
11240747
25.

Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma.

Kudelka AP, Verschraegen CF, Shen Y, Gonzalez De Leon C, Edwards CL, Freedman RS, Forman A, Gibbs HR, Mante R, Hord M, Canetta R, Krakoff I, Kavanagh JJ.

Int J Gynecol Cancer. 1999 Jan;9(1):44-53.

PMID:
11240742
26.

Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.

Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF.

Clin Exp Metastasis. 2000;18(1):83-8.

PMID:
11206843
27.

Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.

Verschraegen CF, Levenback C, Vincent M, Wolf J, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ.

Ann N Y Acad Sci. 2000;922:349-51. No abstract available.

PMID:
11193920
28.

Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.

Verschraegen CF, Vincent M, Abbruzzese JL, Siegler D, Kavanagh JJ, Loyer E, Kudelka AP, Rubin E.

Ann N Y Acad Sci. 2000;922:345-8. No abstract available.

PMID:
11193919
29.

Limitations of size as a criterion in the evaluation of adrenal tumors.

Barnett CC Jr, Varma DG, El-Naggar AK, Dackiw AP, Porter GA, Pearson AS, Kudelka AP, Gagel RF, Evans DB, Lee JE.

Surgery. 2000 Dec;128(6):973-82;discussion 982-3.

PMID:
11114632
30.

Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides.

Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG.

Cancer Immunol Immunother. 2000 Nov;49(9):459-68.

PMID:
11092612
31.

Estrogen replacement therapy and ovarian cancer.

Sittisomwong T, Suneja A, Kudelka AP, Verschraegen CF, Kavanagh JJ.

Eur J Gynaecol Oncol. 2000;21(4):348-54. Review.

PMID:
11055480
32.

Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.

Moon C, Verschraegen CF, Bevers M, Freedman R, Kudelka AP, Kavanagh JJ.

Anticancer Drugs. 2000 Aug;11(7):565-8.

PMID:
11036959
33.

SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer.

Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP.

Oncologist. 2000;5(4):302-11.

34.

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes Ed, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ.

J Clin Oncol. 2000 Jul;18(14):2733-9.

PMID:
10894873
35.

Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.

Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.

Clin Cancer Res. 2000 Jun;6(6):2268-78.

36.

Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.

Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelkà AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ.

Ann Intern Med. 2000 Mar 7;132(5):364-8.

PMID:
10691586
37.

Synchronous primary cancers of the breast and cervix: planning multidisciplinary primary treatment [clinico-pathological conference].

Verstovsek S, Verschraegen CF, Edwards CL, Malpica A, Kavanagh JJ, Ross MI, Strom EA, Jhingran A, Theriault RL, Kudelka AP.

Am J Clin Oncol. 2000 Feb;23(1):99-103.

PMID:
10683089
38.

Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.

Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW, Ioannides CG.

Anticancer Res. 1999 Jul-Aug;19(4B):2907-16.

PMID:
10652572
39.

Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.

Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG.

Clin Cancer Res. 1999 Dec;5(12):4214-23.

40.

Tamoxifen-induced thrombocytopenia.

Yao JC, Thomakos N, McLaughlin P, Buchholz TA, Kudelka AP.

Am J Clin Oncol. 1999 Oct;22(5):529-32. Review.

PMID:
10521073
41.

Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness.

Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC Jr, Goldstein MG, Novack D, Lenzi R.

Cancer. 1999 Sep 1;86(5):887-97.

PMID:
10463990
42.

Discussing disease progression and end-of-life decisions.

Baile WF, Glober GA, Lenzi R, Beale EA, Kudelka AP.

Oncology (Williston Park). 1999 Jul;13(7):1021-31; discussion 1031-6, 1038. Review.

43.

Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex.

Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, Kudelka AP, Wharton JT, Ioannides CG.

Mol Immunol. 1998 Dec;35(17):1121-33.

PMID:
10395201
44.

A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS.

Anticancer Drugs. 1999 Apr;10(4):375-83.

PMID:
10378672
45.

Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.

Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.

Clin Cancer Res. 1999 May;5(5):953-61.

46.

Topoisomerase-I inhibitors in gynaecologic tumours.

Verschraegen CF, Kudelka AP, Kavanagh JJ.

Ann Acad Med Singapore. 1998 Sep;27(5):683-7. Review.

PMID:
9919340
47.

Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.

Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJ.

Anticancer Drugs. 1998 Jul;9(6):577-9.

PMID:
9877247
48.

Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.

Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG.

Ann Surg Oncol. 1998 Dec;5(8):743-50.

PMID:
9869522
49.

Anaplastic carcinoma of the fimbriated end of the fallopian tube as an incidental finding.

Gerson R, Serrano A, Dolengevich H, De Leon B, Villalobos A, Kavanagh JJ, Kudelka AP.

Eur J Gynaecol Oncol. 1998;19(5):431-3.

PMID:
9863904
50.

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ.

Clin Cancer Res. 1997 Sep;3(9):1501-5.

Supplemental Content

Loading ...
Support Center